The new WHO recommendations ignore one of Robert F. Kennedy Jr.'s biggest priorities.
Oct 7 (Reuters) - Zealand Pharma said on Wednesday its experimental drug helped people who are overweight or obese and have type 2 diabetes lose up to 9.2% of their body weight in a mid-stage trial.
A new global definition of clinical obesity classifies far fewer children as obese than widely used body mass index (BMI) ...
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the ...
The World Health Organization (WHO) today released its first guidelines addressing the sharp rise in obesity among children and adolescents, setting out how health systems and health workers can ...
A new global definition of clinical obesity classifies far fewer children as obese than the widely used body mass index (BMI) ...
Glucagon-like peptide-1 receptor agonists improve obstructive sleep apnea outcomes in obesity, primarily through significant weight loss.
Obesity Canada released a national benchmark report finding that access to obesity care in Canada is shaped by geography, ...
The number of obese children has quadrupled since 1990 prompting the WHO to take action by issuing treatment guidelines.
Researchers published late-stage clinical trial data today for the latest obesity drug, retatrutide—expected to be the most ...
Eli Lilly and Company stocks have been trading up by 4.07 percent after promising trial data boosted obesity drug optimism.
No. 54 / 2026 Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results